Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) reached a new 52-week low on Thursday . The company traded as low as $8.91 and last traded at $10.40, with a volume of 592113 shares traded. The stock had previously closed at $9.37.
Analysts Set New Price Targets
BCAX has been the subject of several research reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.01 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Stifel Nicolaus set a $48.00 price target on shares of Bicara Therapeutics in a report on Thursday, March 27th. HC Wainwright decreased their price objective on shares of Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating for the company in a research report on Monday, April 7th. Finally, Wedbush reaffirmed an "outperform" rating and set a $31.00 price target on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $36.50.
Check Out Our Latest Analysis on BCAX
Bicara Therapeutics Stock Up 0.4 %
The company has a 50 day moving average price of $12.74 and a 200 day moving average price of $16.66.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.08). Sell-side analysts expect that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.
Hedge Funds Weigh In On Bicara Therapeutics
Several hedge funds have recently added to or reduced their stakes in BCAX. California State Teachers Retirement System purchased a new stake in Bicara Therapeutics in the 4th quarter valued at $25,000. Spire Wealth Management acquired a new position in Bicara Therapeutics in the fourth quarter valued at $31,000. BNP Paribas Financial Markets purchased a new stake in shares of Bicara Therapeutics in the fourth quarter valued at about $32,000. Legal & General Group Plc acquired a new stake in shares of Bicara Therapeutics during the fourth quarter worth about $33,000. Finally, Summit Investment Advisors Inc. purchased a new position in shares of Bicara Therapeutics during the fourth quarter worth about $35,000.
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Read More
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
